ANGE-S003 / Angecon Biotech - LARVOL DELTA

Phase 1 study of safety and preliminary efficacy of intranasal transplantation of human neural stem cells (ANGE-S003) in Parkinson's disease. (PubMed, J Neurol Neurosurg Psychiatry) - "Treatment with ANGE-S003 is feasible, generally safe and well tolerated, associated with functional improvement in clinical outcomes with peak efficacy achieved at month 6. Intranasal transplantation of neural stem cells represents a new avenue for the treatment of PD, and a larger, longer-term, randomised, controlled phase 2 trial is warranted for further investigation."

Journal • P1 data • CNS Disorders • Movement Disorders • Parkinson's Disease • Transplantation